Analysis of ANC recovery from a Phase III study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

被引：0
|
作者：
Bondarenko, I. [1 ]
Bias, P. [2 ]
Elsaesser, R. [2 ]
Buchner, A. [2 ]
机构：
[1] Dnepropetrovsk Municipal Clin Hosp 4, Dnepropetrovsk, Ukraine
[2] Teva Ratiopharm, Ulm, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1961
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [11] SAFETY AND TOLERABILITY OF LIPEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: AN INTEGRATED ANALYSIS OF PHASE II AND III STUDIES
    Gladkov, O.
    Elsaesser, R.
    Buchner, A.
    Bias, P.
    Mueller, U.
    HAEMATOLOGICA, 2013, 98 : 422 - 422
  • [12] Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
    Jeon, Ye Won
    Lim, Seung Taek
    Gwak, HongKi
    Park, Seon Young
    Suh, Young Jin
    JOURNAL OF BREAST CANCER, 2020, 23 (05) : 521 - 532
  • [13] Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: An integrated analysis from the phase II and phase III studies
    Bondarenko, I.
    Bias, P.
    Elsaesser, R.
    Buchner, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S443 - S444
  • [14] Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies
    Bondarenko, I. M.
    Bias, P.
    Buchner, A.
    SUPPORTIVE CARE IN CANCER, 2016, 24 (01) : 267 - 273
  • [15] Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies
    I. M. Bondarenko
    P. Bias
    A. Buchner
    Supportive Care in Cancer, 2016, 24 : 267 - 273
  • [16] A MULTICENTER RANDOMIZED PHASE III STUDY OF KRN125 (PEGFILGRASTIM) IN BREAST CANCER PATIENTS RECEIVING TC CHEMOTHERAPY
    Rai, Y.
    Sagara, Y.
    Kuranami, M.
    Masuda, N.
    Takano, T.
    Saeki, T.
    Nakamura, S.
    Ito, Y.
    Tokuda, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2013, 24 : 13 - 13
  • [17] Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy
    Zou, Linglong
    Buchner, Anton
    Roberge, Martin
    Liu, Patrick M.
    JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016
  • [18] Phase-III trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide for primary breast cancer
    Mross, Klaus
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (04) : 253 - 254
  • [19] A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer
    Lee, Keun Seok
    Ro, Jungsil
    Nam, Byung-Ho
    Lee, Eun Sook
    Kwon, Youngmee
    Kwon, Hye Soo
    Chung, Ki Wook
    Kang, Han Sung
    Kim, Eun A.
    Kim, Seok Won
    Shin, Kyung Hwan
    Kim, Seok-Ki
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 481 - 489
  • [20] A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer
    Keun Seok Lee
    Jungsil Ro
    Byung-Ho Nam
    Eun Sook Lee
    Youngmee Kwon
    Hye Soo Kwon
    Ki Wook Chung
    Han Sung Kang
    Eun A Kim
    Seok Won Kim
    Kyung Hwan Shin
    Seok-Ki Kim
    Breast Cancer Research and Treatment, 2008, 109 : 481 - 489
12345